Using data to guide anticoagulation in patients with atrial fibrillation: Does the analysis fit the question?

JAMA Cardiology

Volumn 1, Issue 2, 2016, Pages 121-122

  Alexander, John H ^a   Thomas, Laine E ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; EDITORIAL; FOLLOW UP; HUMAN; INTERNATIONAL NORMALIZED RATIO; PREDICTION; SWEDEN; TREATMENT OUTCOME; FIBRINOLYTIC THERAPY;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; THROMBOLYTIC THERAPY; WARFARIN;

EID: 84993986729     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.0198     Document Type: Editorial

References (15)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857-867.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-1151.
3. Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-891.
4. Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-992.
5. Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-2104.
6. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996; 335(8):540-546.
7. Björck F, Renlund H, Lip GYH, Wester P, Svensson PJ, Själander A. Outcomes in a warfarin-treated population with atrial fibrillation [published online April 20, 2016]. JAMA Cardiol. doi:10.1001/jamacardio.2016.0199.
8. Björck F, Sandén P, Renlund H, Svensson PJ, Själander A. Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden. Thromb Res. 2015; 136(2):216-220.
9. Singer DE, Hellkamp AS, Piccini JP, et al.; ROCKET AF Investigators. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013; 2(1):e000067.
10. Alexander JH, Lopes RD, Thomas L, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014; 35(4):224-232.
11. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012; 33(22):2821-2830.
12. Piccini JP, Stevens SR, Chang Y, et al.; ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (An Ticoagulation and Risk factors In Atrial fibrillation) Study cohorts. Circulation. 2013; 127(2): 224-232.
13. Wallentin L, Lopes RD, Hanna M, et al.; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013; 127(22):2166-2176.
14. Wallentin L, Yusuf S, Ezekowitz MD, et al.; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376(9745):975-983.
15. Piccini JP, Hellkamp AS, Lokhnygina Y, et al.; ROCKET AF Investigators. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc. 2014; 3(2):e000521.